A Phase 1 interventional study of Teneligliptin 20mg/day and Atorvastatin 40mg/Day in Diabete Mellitus, sponsored by Handok Inc.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-30.
Sponsored by Handok Inc. · Phase 1, Interventional, and Other
A randomized, open-label, cross-over, multiple dosing study to evaluate drug-drug interaction between Teneligliptin and Atorvastatin in healthy male adults
10,923 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.
This study's enrollment of 30 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Handok Inc. is the lead sponsor of 45 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Drug: Teneligliptin 20mg/day
Drug: Atorvastatin 40mg/Day
Drug: Teneligliptin 20mg/day + Atorvastatin 40mg/day
cross-over
cross-over
cross-over
Cmax,ss(Maximum concentration at steady state)
Time frame: 24 hours
AUCτ,ss(Area under the concentration-time curve at steady state)
Time frame: 24hours
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Handok Inc.